The U.S. conducts nearly 2 million coronavirus tests daily. A new analysis shows millions more are needed to protect the most vulnerable. Use our tool to see how your state is doing.
A comprehensive dataset gives the American public the same view of the status of the pandemic that federal officials have but previously held back. The outlook is bleak.
Science writer Robin Marantz Henig has written about dangerous emerging pathogens for 30 years. But none of what she learned could shed light on her own confusing encounter with this virus.
Advisers to the Food and Drug Administration voted 20-0 to recommend that the agency authorize Moderna's vaccine for emergency use during the pandemic. There was a single abstention.
Atlantic writer Ed Yong says the COVID-19 vaccination program will be the most complicated the U.S. has ever attempted: "It's going to be a slow process, and there are a lot of possible roadblocks."
Two days before a panel of experts is set to review Moderna's COVID-19 vaccine and advise the Food and Drug Administration, documents show the vaccine is 94% effective and well-tolerated.
States are starting to administer their first doses of Pfizer's newly FDA-authorized COVID-19 vaccine. It marks a new phase in the pandemic, but what's that mean for you?
Eleven months into the COVID-19 crisis, an unimaginable death toll has been reached. NPR spoke to doctors, nurses and the bereaved about how they face loss every day.
The power of family history can lead a person to do a lot of things. For Howard Berkes, the family tradition of facing crises head-on led him to sign up for experimental testing of a COVID-19 vaccine.
Officials may be relying on people to do their part to stop the spread of COVID-19 at a time when the public is simply not afraid enough anymore to keep up the recommended behaviors.
In the U.S., front-line health care workers are likely first in line to get immunized with a COVID-19 vaccine, once the FDA says yes. But what about the rest of us? Here's what we know so far.
In a 17-4 vote, an expert committee concluded that the scientific evidence supports the authorization of the COVID-19 vaccine from Pfizer and BioNTech for emergency use during the pandemic.
The Food and Drug Administration finds "no specific safety concerns" that would stand in the way of authorization of the vaccine for emergency use. Effectiveness is 95% after two doses.